Correlation Between Moleculin Biotech and Spyre Therapeutics

Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Moleculin Biotech and Spyre Therapeutics, you can compare the effects of market volatilities on Moleculin Biotech and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Spyre Therapeutics.

Diversification Opportunities for Moleculin Biotech and Spyre Therapeutics

0.5

Correlation Coefficient

Moleculin Biotech  Spyre Therapeutics

Very weak diversification

The 3 months correlation between Moleculin and Spyre is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Moleculin Biotech and Spyre Therapeutics

Given the investment horizon of 90 days Moleculin Biotech is expected to generate 7.98 times more return on investment than Spyre Therapeutics. However, Moleculin Biotech is 7.98 times more volatile than Spyre Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about -0.1 per unit of risk. If you would invest  173.00  in Moleculin Biotech on December 21, 2024 and sell it today you would lose (64.00) from holding Moleculin Biotech or give up 36.99% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Moleculin Biotech  vs.  Spyre Therapeutics

Moleculin Biotech

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Moleculin Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Moleculin Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Spyre Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Moleculin Biotech and Spyre Therapeutics

The main advantage of trading using opposite Moleculin Biotech and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.

The idea behind Moleculin Biotech and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.